Clinical Trials

EGFR-mutant Non-small Cell Lung Cancer

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

66 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05110196 2025-12-03

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Phase 4 Completed

50 enrolled

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04926831 2025-10-16

Geometry-N

4 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04677595 2025-06-24

GeoMETry-C

37 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04427072 2025-05-16

GeoMETry-III

Phase 3 Terminated

22 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT04139317 2024-10-09

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

76 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT04323436 2024-10-09

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

31 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT05567055 2024-06-17

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05435846 2024-06-11

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Phase 1 Terminated

3 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

373 enrolled 34 charts 3 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02335944 2023-06-18

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Phase 1/2 Terminated

177 enrolled 48 charts

Carcinoma, Non-Small-Cell Lung

NCT02323126 2022-02-28

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

64 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

18 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01911507 2021-10-13

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Phase 1 Completed

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04460729 2020-12-03

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase 2 Withdrawn